Production of T-cell progenitor cells from healthy volunteers

Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors

This study is testing a way to produce special immune cells from healthy young men to help improve treatments for diseases.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 14 (estimated)
• Ages: 18 Years to 40 Years
• Sex: Male
• Sponsor: Smart Immune SAS (Industry-sponsored)
• Locations: 1 site (Paris)
• Trial ID: NCT05118113 on ClinicalTrials.gov

What this trial studies

This study aims to finalize the development of a process for producing T-cell progenitor cells by collecting mobilized hematopoietic stem cells from healthy volunteers. The study will involve healthy male donors aged 18 to 40 years who meet specific health criteria. Participants will undergo apheresis to collect the necessary stem cells, which are crucial for advancing research in immunotherapy and regenerative medicine.

Who should consider this trial

Good fit: Ideal candidates for this study are healthy male volunteers aged 18 to 40 years with a body weight of at least 65 kg and a BMI between 20 and 30.

Not a fit: Patients who are not healthy or do not meet the specific age, weight, and health criteria will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the availability of T-cell progenitor cells for therapeutic applications in various diseases.

How similar studies have performed: While the specific approach of this study may be novel, similar studies in the field of T-cell production have shown promise in advancing cell therapies.

Eligibility criteria

Inclusion Criteria:

* Healthy donors, men aged 18 to 40 years.
* Body weight ≥ 65 kg with a body mass index (BMI) calculated by weight in kg/(height in m)² of 20 to 30 kg/m² at screening.
* Informed consent form signed and dated prior to any study-specific screening procedure.
* Health status judged by the investigator to be compatible with participation in the study based on medical history, results of physical examination, results of biological laboratory tests (cell blood count including RBC, hematocrit, hemoglobin, reticulocytes, WBC, platelet, PT, aPTT, CRP, fasting blood glucose, ionogram (Na+, K+, Cl-, HCO3-), creatinine, creatinine clearance by Cockcroft, albumin, total protein, total bilirubin, AST, ALT, ALP, GGT), vital signs measurements and 12-lead ECG. All results should be normal or, if out of range, clinically insignificant in the judgement of the investigator.
* Venous capital compatible with leukapheresis
* Have a high probability of complying with and completing the study.
* Be affiliated with a Social Security scheme

Exclusion Criteria:

* Any cardiovascular (e.g. heart failure), hepatic, renal, respiratory (e.g. asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunological, dermatological, haematological (including hemoglobinopathy), neurological, psychiatric disorder or any history of allergy to a drug.
* State of acute illness (e.g., vomiting, fever, diarrhea) within 7 days prior to the first day of the study.
* History of drug abuse in the year preceding the first day of the study.
* History of alcoholism in the year prior to day 1 defined as consumption of more than 3 standard drinks/day (30 g/day) or 15 standard drinks/week (150 g/week) or less than two non-alcoholic days each week, or more than 5 standard drinks (50 g) on a single occasion.
* Any contra-indication to filgrastim
* Positive serological results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, syphilis and/or human T-lymphotropic virus (HTLV).
* Positive urine drug tests (methadone, barbiturates, benzodiazepines, tricyclic antidepressants, cocaine, cannabinoids, morphine, amphetamines and methamphetamines, including 3,4-methylenedioxy-N-methylamphetamine \[MDMA\]).
* Laboratory workup including blood count, fasting blood glucose, blood ionogram, creatinine, AST, ALT, gamma GT, alkaline phosphatase, total bilirubin, CRP, PT, aPTT incompatible with leukapheresis protocol.
* Use of any experimental drug within 30 days prior to inclusion.
* Use of any prescription or over-the-counter medication within 5 times the elimination half-life prior to inclusion. However, any prescribed medication that may interfere with the study objectives must be discontinued for at least 30 days.

Where this trial is running

Paris

• CIC Paris Est, Hôpital Pitié Salpêtrière — Paris, France (Recruiting)

Study contacts

• Principal investigator: Joe-Elie Salem, MD, PhD — CIC Paris Est, Hôpital Pitié Salpêtrière, Paris
• Study coordinator: Aurelie Bauquet, PhD

Conditions Healthy Volunteers